EDGAR·FLOW

MAIA Biotechnology, Inc. — Form 8-K

Filed November 17, 2026 · analyzed by the 8-K Agent
8-K ▲ Likely positive significance 72/100
What the filing says
MAIA Biotechnology announced interim efficacy data from Part C of its Phase 2 THIO-101 trial of ateganosine (telomere-targeting agent) in third-line non-small cell lung cancer. Combined data from Parts A, B, and C show 88% disease control rate (38 of 43 patients) as of October 1, 2026, substantially exceeding the 25–35% DCR for standard third-line chemotherapy. The company is completing Part C enrollment across seven countries and advancing the pivotal Phase 3 THIO-104 trial toward 2027 interim survival analysis.
Why this rating

Clinical efficacy data materially advance lead asset relative to company scale ($48.9M market cap). Phase 3 initiation and Fast Track status de-risk regulatory path; magnitude of DCR advantage (88% vs. 25–35%) is compelling for late-stage cancer therapy but remains early-stage (Phase 2 interim). Stock-price-positive news, though regulatory and OS confirmation remain critical unknowns.

Tradability signal
NO TRADE

No trade: already up 8.3% on the news and the fade evidence is too weak. Similar past filings (543 in this cell) moved -0.26% in the called direction over 4 hrs; shrunk for sample size that's a -0.25% edge. (Filing arrived outside market hours — evaluated at the next open with a live quote.)

Derived from this site's own measured outcomes + live price/liquidity at analysis time. An experiment, not investment advice.

Price action (we called it positive)
before filing · preread
$1.02 ▲ 0.99%
at our read · unknown
$1.01
+10 min · unknown
$1.10 ▲ 8.91%
+30 min · unknown
$1.11 ▲ 9.90%
+1 hr · unknown
$1.15 ▲ 13.86%
+4 hrs · unknown
$1.23 ▲ 21.29%

The stock had already moved -0.98% between hitting EDGAR and our read finishing — deltas above are measured from our read.

Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →

View original filing on SEC.gov ↗ MAIA · stock on Yahoo Finance ↗

See more from November 17, 2026.

EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.